Inhibrx
INBX
101 hedge funds and large institutions have $172M invested in Inhibrx in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 11 closing their positions.
206% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $418K
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
23% more capital invested
Capital invested by funds: $139M → $172M (+$32.6M)
15.66% more ownership
Funds ownership: 61.45% → 77.11% (+16%)
5% more funds holding
Funds holding: 96 → 101 (+5)
7% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$10M |
| 2 |
BlackRock
New York
|
+$1.75M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 5 |
Goldman Sachs
New York
|
+$544K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.04M |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$631K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$564K |
| 4 |
Millennium Management
New York
|
-$472K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$453K |
INBX Hedge Fund Activity: Q4 2024 in Review
101 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q4 2024, worth a combined $172M — up 23% from $139M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new INBX positions and 11 closed out — a net gain of 6 holders — while 31 added to existing stakes and 29 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $10M. The largest seller was Morgan Stanley, cutting an estimated $3.04M.
- 101 institutional investors held Inhibrx (INBX) as of Q4 2024, up from 96 in Q3 2024.
- Funds reported $172M of Inhibrx stock for Q4 2024, up 23% quarter-over-quarter.
- 17 funds opened new Inhibrx positions in Q4 2024 and 11 closed out, a net change of +6 holders.
- The largest Inhibrx buyer in Q4 2024 was HighTower Advisors, an estimated $10M added.
- The largest Inhibrx seller in Q4 2024 was Morgan Stanley, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2024.